<a href="https://laohu8.com/S/FBLG">FibroBiologics</a> Announces Upcoming Phase 1/2 Clinical Trial for Innovative Diabetic Foot Ulcer Therapy at Advanced Wound Care <a href="https://laohu8.com/S/SMMT">Summit</a>
FibroBiologics Inc. has announced the upcoming presentation of their recent research advances at the Advanced Wound Care Summit USA in Boston, Massachusetts. The company's Founder and CEO, Pete O'Heeron, is set to present on July 15, 2025, focusing on fibroblast-based technology for wound healing and psoriasis. The presentation will highlight FibroBiologics' CYWC628 therapy, which represents a novel approach to treating diabetic foot ulcers by leveraging the body's natural regenerative processes. This therapy is part of their Phase 1/2 clinical trial, which is scheduled to begin later this year. The summit will feature various industry leaders discussing innovations in wound care and is an opportunity for FibroBiologics to showcase their potential contributions to the field. Results of the clinical trial have not yet been presented as the trial is still in preparation.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fibrobiologics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9492657-en) on July 11, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。